- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07237308
BEACON-AA: Apixaban met of zonder Clopidogrel bij Beroertepatiënten met Atriumfibrilleren en Cerebrale Atherosclerose
Een multicenter prospectief gerandomiseerd onderzoek naar de effectiviteit van apixaban en clopidogrel ter voorkoming van recidiverende ischemische beroerte bij patiënten met atriumfibrilleren en cerebrale atherosclerose
This trial aims to compare the safety and efficacy of apixaban alone versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomly assigned in a 1:1 ratio to receive apixaban monotherapy or dual therapy with clopidogrel for 30 days. The primary outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30 (±5) days compared with baseline MRI, adjudicated by a central committee.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Although oral anticoagulants are effective in preventing cardioembolic stroke in patients with non-valvular atrial fibrillation (NVAF), a considerable proportion of ischemic strokes in these patients are caused by concomitant large artery atherosclerosis. Carotid or intracranial artery stenosis is present in a substantial number of patients with NVAF and is associated with a higher risk of recurrent cerebral infarction despite standard anticoagulation. In such patients, adding an antiplatelet agent to oral anticoagulation may theoretically reduce atherothrombotic events, but it also raises concern for increased bleeding risk. Recent clinical evidence on this issue remains limited, and the optimal antithrombotic strategy for patients with NVAF and coexisting symptomatic atherosclerotic stenosis has not been clearly established.
The BEACON-AA trial is a multicenter, randomized, open-label, blinded-endpoint (PROBE) study designed to compare the safety and efficacy of apixaban monotherapy versus apixaban combined with clopidogrel in patients with acute ischemic stroke associated with non-valvular atrial fibrillation (NVAF) and concomitant symptomatic intracranial or extracranial atherosclerosis or complex plaque in the ascending aorta or aortic arch (≥4 mm in thickness, mobile, or ulcerated). Participants will be randomized in a 1:1 ratio to receive apixaban alone or apixaban plus clopidogrel for 30 days, followed by apixaban monotherapy thereafter.
Brain MRI including diffusion-weighted and FLAIR sequences will be performed at baseline and at 30 ± 5 days to assess new or recurrent ischemic lesions. The primary efficacy outcome is the incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee. Secondary efficacy outcomes include: 1) incidence of symptomatic ischemic stroke or transient ischemic attack within 90 days, 2) incidence of acute coronary syndrome within 90 days,3) cardiovascular mortality within 90 days, 4) composite major cardiovascular events within 90 days, 5) all-cause mortality within 90 days, 6) proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, and 7) proportion of patients with mRS 0-3 at 90 days. The primary safety outcomes are: 1) incidence of major bleeding within 90 days, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria and 2) incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE)) at 30 ± 5 days after randomization. All imaging and clinical events will be independently adjudicated by blinded central adjudication committees.
Studietype
Inschrijving (Geschat)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Young Dae Kim, M.D. Ph.D.
- Telefoonnummer: 02-2228-1619
- E-mail: NEURO05@YUHS.AC
Studie Locaties
-
-
-
Busan, Zuid -Korea
- Werving
- Pusan National University Hospital
-
Contact:
- Han-Jin Cho, Professor
- Telefoonnummer: '+82--51-240-7000
- E-mail: chohj75@gmail.com
-
Busan, Zuid -Korea
- Werving
- Dong-A University Hospital
-
Contact:
- Jung Hwa Seo, Professor
- Telefoonnummer: +82-51-240-2000
- E-mail: jhseo34@gmail.com
-
Chuncheon, Zuid -Korea
- Werving
- Hallym University Chuncheon Sacred Heart Hospital
-
Contact:
- Chulho Kim, Professor
- Telefoonnummer: +82-33-240-5000
- E-mail: gumdol52@naver.com
-
Daegu, Zuid -Korea
- Werving
- Keimyung University Dongsan Hospital
-
Contact:
- Sung-Il Sohn, Professor
- Telefoonnummer: +82-1577-6622
- E-mail: sungil.sohn@gmail.com
-
Goyang, Zuid -Korea
- Werving
- National Health Insurance Service Ilsan Hospital
-
Contact:
- Gyu Sik Kim, Professor
- Telefoonnummer: '+82-1577-0013
- E-mail: myoungsim@naver.com
-
Incheon, Zuid -Korea
- Werving
- Inha University Hospital
-
Contact:
- Hee-Kwon Park, Professor
- Telefoonnummer: '+82-32-890-2114
- E-mail: parkhkwon@gmail.com
-
Incheon, Zuid -Korea
- Werving
- Gachon University Gil Medical Center
-
Contact:
- Sang Hee Ha, Professor
- Telefoonnummer: +82-1577-2299
- E-mail: shha31@naver.com
-
Incheon, Zuid -Korea
- Werving
- Catholic Kwandong University International St. Mary's Hospital
-
Contact:
- Sang-Jun Ahn, Professor
- Telefoonnummer: +82-1600-8291
- E-mail: neuroan@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Samsung Medical Center
-
Contact:
- Woo-Keun Seo, Professor
- Telefoonnummer: '+82-2-2-3410-2114
- E-mail: mcastenosis@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Seoul National University Hospital
-
Contact:
- Keun-Hwa Jung, Professor
- Telefoonnummer: +82-1588-5700
- E-mail: jungkh@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Korea University Anam Hospital
-
Contact:
- Sungwook Yu, Professor
- Telefoonnummer: '+82-1577-0083
- E-mail: song4yu@korea.ac.kr
-
Seoul, Zuid -Korea
- Werving
- Kangbuk Samsung Hospital
-
Contact:
- Jang-Hyun Baek, Professor
- Telefoonnummer: '+82-1599-8114
- E-mail: janghyun.baek@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Ewha Womans University Seoul Hospital
-
Contact:
- Tae-Jin Song, Professor
- Telefoonnummer: +82-1522-7000
- E-mail: knstar@hanmail.net
-
Seoul, Zuid -Korea
- Werving
- Gangnam Severance Hospital
-
Contact:
- Yo Han Jung, Professor
- Telefoonnummer: +82-1599-6114
- E-mail: YHJUNG@yuhs.ac
-
Seoul, Zuid -Korea
- Werving
- Hanyang University Seoul Hospital
-
Contact:
- Young Seo Kim, Professor
- Telefoonnummer: +82-2-2290-8114
- E-mail: aescula@hanmail.net
-
Seoul, Zuid -Korea
- Werving
- Kyung Hee University Hospital
-
Contact:
- Jung Hyun Park, Professor
- Telefoonnummer: +82-2-958-8114
- E-mail: truelove1@hanmail.net
-
Seoul, Zuid -Korea
- Werving
- Kyung Hee University Hospital at Gangdong
-
Contact:
- Il Hyung Lee, Professor
- Telefoonnummer: +82-1577-5800
- E-mail: neu210@naver.com
-
Seoul, Zuid -Korea
- Werving
- Inje University Sanggye Paik Hospital
-
Contact:
- Sang Won Han, Professor
- Telefoonnummer: '+82-2-950-1114
- E-mail: sah1puyo@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Kangdong Sacred Heart Hospital
-
Contact:
- Yerim Kim, Professor
- Telefoonnummer: +821588-4100
- E-mail: brainyrk@gmail.com
-
Seoul, Zuid -Korea
- Werving
- Yonsei University College of Medicine
-
Contact:
- Young Dae Kim, Professor
- Telefoonnummer: +82-2-2228-1619
- E-mail: NEURO05@YUHS.AC
-
Yŏngin, Zuid -Korea
- Werving
- Yongin Severance Hospital
-
Contact:
- Jinkwon Kim, Professor
- Telefoonnummer: +82-1899-1004
- E-mail: ANTITHROMBUS@yuhs.ac
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Adults aged 19 years or older at the time of enrollment.
-
Patients with non-valvular atrial fibrillation (NVAF) documented by electrocardiography.
-
Acute ischemic stroke confirmed by brain MRI (diffusion-weighted and FLAIR sequences), with last known well within 120 hours prior to randomization.
-
Presence of clinically significant atherosclerosis in the cerebral or aortic arteries, meeting at least one of the following criteria:
① ≥30% stenosis in the relevant artery (the artery supplying the infarcted territory) demonstrated by CTA, MRA, or DSA - using the WASID criteria for intracranial arteries and NASCET criteria for extracranial arteries.
② High-risk atherosclerotic plaque features in the relevant artery demonstrated by CTA, MRA, or ultrasound, such as ulceration, intraplaque hemorrhage, mobile plaque, or a large lipid core (involving ≥25% of plaque cross-sectional area) on CTA/MRA, or ulceration, mobile plaque, or hypoechoic/echolucent plaque on ultrasound; or presence of branch artery occlusive disease (BAOD).
③ Complex aortic plaque (≥4 mm in thickness, mobile, or ulcerative) identified in the ascending aorta or aortic arch by transthoracic/transesophageal echocardiography or coronary CT angiography.
-
Written informed consent provided by the participant or a legally authorized representative.
Exclusion Criteria:
- Presence of mechanical heart valves or rheumatic mitral stenosis.
- Requirement for antithrombotic agents other than apixaban and clopidogrel.
- Planned percutaneous coronary intervention, coronary artery bypass graft surgery, carotid endarterectomy, or intracranial stenting within 3 months after enrollment.
- Presence of mural thrombus in the heart confirmed by imaging.
- Renal impairment with creatinine clearance ≤25 mL/min.
- Severe hepatic impairment, including acute hepatitis, chronic active hepatitis, hepatic lesions or coagulopathy, hepatic failure, or laboratory evidence of AST/ALT >2× the upper limit of normal (ULN) or total bilirubin ≥1.5× ULN.
- Small-vessel occlusion (lacunar infarction) according to the TOAST classification.
- History within the past 30 days of gastrointestinal bleeding, vascular malformation of the brain or spinal cord, recent brain, spinal, or ophthalmologic surgery or trauma, esophageal varices, or intracranial hemorrhage at any time; or chronic regular use of NSAIDs (≥3 days per week for ≥2 consecutive weeks).
- Ischemic stroke occurring despite concurrent use of both NOAC and antiplatelet therapy.
- Planned surgery or high-bleeding-risk procedure within 3 months, or presence of active bleeding at enrollment.
- Anemia (hemoglobin < 8.0 g/dL) or thrombocytopenia (platelet count < 100,000/µL).
- Pre-stroke modified Rankin Scale (mRS) ≥ 2.
- Severe comorbid illness or malignancy not in complete remission with an expected life expectancy <1 year.
- Known hypersensitivity or allergy to apixaban or clopidogrel.
- Pregnant or breastfeeding women.
- Uncontrolled diabetes mellitus (HbA1c > 10.0%) or severe hypertension (systolic ≥ 220 mmHg or diastolic ≥ 120 mmHg).
- Concomitant use of strong CYP3A4 and P-glycoprotein inhibitors that can significantly increase apixaban exposure (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin).
- Concomitant use of strong CYP2C19 inducers that can enhance clopidogrel antiplatelet effect and increase bleeding risk (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort).
- Clinically significant mass effect due to space-occupying cerebral infarction, or patients expected to require decompressive craniectomy, including those with midline shift > 5 mm, loss of basal cisterns, herniation, fourth-ventricle compression, or obstructive hydrocephalus in posterior fossa infarcts.
- Intracranial hemorrhage or hemorrhagic transformation (PH1 or PH2) according to ECASS criteria.
- Participation in another interventional clinical trial within the past 30 days or concurrent participation in another interventional study (non-interventional observational or registry studies may be allowed at the investigator's discretion).
- Any other condition that, in the investigator's judgment, would make participation or continued involvement in the study inappropriate or infeasible.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Apixaban and Clopidogrel Combination Therapy
Participants receive apixaban(5mg twice daily, or 2.5mg twice daily if indicated) plus clopidogrel 75mg daily for 30days, followed by apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Andere namen:
Clopidogrel 75mg once daily for 30 days in combination with apixaban, then discontinued.
Andere namen:
|
|
Actieve vergelijker: Apixaban Monotherapy
Participants receive apixaban 5mg(or 2.5mg if indicated) twice daily as monotherapy for 30 days and continue apixaban monotherapy thereafter. |
Apixaban 5mg(or 2.5mg if indicated) twice daily. Used as monotherapy or in combination with clopidogrel for 30 days, then continued as monotherapy.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of new symptomatic or asymptomatic ischemic lesions on DWI/FLAIR at 30(±5) days compared with baseline MRI, adjudicated by a central committee
Tijdsspanne: At 30 ± 5 days after randomization
|
New ischemic lesions, either symptomatic or asymptomatic, identified on DWI/FLAIR at 30 (±5) days compared with baseline MRI, as adjudicated by a central adjudication committee. |
At 30 ± 5 days after randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of symptomatic ischemic stroke or transient ischemic attack (TIA)
Tijdsspanne: Within 90 days after randomization
|
Occurrence of new symptomatic ischemic stroke or transient ischemic attack confirmed by clinical and/or imaging criteria. |
Within 90 days after randomization
|
|
Incidence of acute coronary syndrome (ACS)
Tijdsspanne: Within 90 days after randomization
|
Occurrence of acute coronary syndrome, including unstable angina or myocardial infarction, confirmed by standard diagnostic criteria. |
Within 90 days after randomization
|
|
Cardiovascular mortality
Tijdsspanne: Within 90 days after randomization
|
Death due to fatal stroke, fatal myocardial infarction, or sudden death not clearly attributed to non-vascular causes. |
Within 90 days after randomization
|
|
Composite major cardiovascular events
Tijdsspanne: Within 90 days after randomization
|
Composite of recurrent stroke (ischemic or hemorrhagic), acute coronary syndrome, or cardiovascular death. |
Within 90 days after randomization
|
|
All-cause mortality
Tijdsspanne: Within 90 days after randomization
|
Death from any cause during the 90-day follow-up period. |
Within 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-2
Tijdsspanne: At 90 days after randomization
|
Functional independence defined as mRS score of 0-2 at day 90. |
At 90 days after randomization
|
|
Proportion of patients with modified Rankin Scale (mRS) score 0-3
Tijdsspanne: At 90 days after randomization
|
Favorable functional outcome defined as mRS score of 0-3 at day 90. |
At 90 days after randomization
|
|
Incidence of major bleeding events according to the ISTH criteria
Tijdsspanne: Within 90 days after randomization
|
Major bleeding events defined by the International Society on Thrombosis and Haemostasis (ISTH) criteria, including fatal bleeding, symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, bleeding resulting in inability to perform usual activities, bleeding requiring transfusion of ≥2 units of whole blood or red cells, or bleeding leading to hospitalization. |
Within 90 days after randomization
|
|
Incidence of new asymptomatic cerebral hemorrhages detected on brain MRI(MR-Diffusion/FLAIR/SWI (or GRE))
Tijdsspanne: At 30 ± 5 days after randomization
|
Newly developed asymptomatic cerebral hemorrhages identified on MR-Diffusion/FLAIR/SWI(or GRE) performed 30 ± 5 days after randomization. |
At 30 ± 5 days after randomization
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Pathologische processen
- Hartziekten
- Aritmieën, hart
- Arteriële occlusieve ziekten
- Intracraniële arteriële aandoeningen
- Pathologische aandoeningen, tekenen en symptomen
- Hartinfarct
- Ischemie
- Boezemfibrilleren
- Arteriosclerose
- Intracraniële arteriosclerose
- Zwavelverbindingen
- Organische chemicaliën
- Pyridines
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Thiophenes
- Ticlopidine
- Thienopyridines
- Clopidogrel
- Apixaban
Andere studie-ID-nummers
- 4-2025-0697
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .